Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLERDOG SWEDEN
2024-517649-15-00Phase 4Authorised
- Sponsor
- Karolinska Institutet
- Start
- Jan 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Dog Allergen Extract in allergic rhinitis (AR) and allergic conjunctivitis (AC), sponsored by Karolinska Institutet. Planned start Jan 2025; status: authorised.
02
Drugs
Dog Allergen Extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2024-517649-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517649-15-00.